Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of human immunodeficiency virus (HIV) infection; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr; Tizona; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos; Janssen; Japan Tobacco, Inc.; Gadeta; Bristol-Myers Squibb Company; Merck; and Novo Nordisk A/S. The company was founded in 1987 and is headquartered in Foster City, California.
IPO Year: 1992
Exchange: NASDAQ
Website: gilead.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/10/2025 | $87.00 → $113.00 | Equal-Weight → Overweight | Morgan Stanley |
| 12/10/2024 | $109.00 | Buy | BofA Securities |
| 11/15/2024 | $110.00 | Outperform | Wolfe Research |
| 11/14/2024 | $125.00 | Buy | Citigroup |
| 11/8/2024 | Buy → Hold | Maxim Group | |
| 10/21/2024 | $74.00 → $96.00 | Market Perform → Outperform | Leerink Partners |
| 10/17/2024 | $105.00 | Outperform | Bernstein |
| 10/7/2024 | $78.00 → $100.00 | Equal Weight → Overweight | Wells Fargo |
| 7/8/2024 | $93.00 | Mkt Perform → Outperform | Raymond James |
| 5/1/2024 | $90.00 → $85.00 | Buy | Maxim Group |
Morgan Stanley upgraded Gilead Sciences from Equal-Weight to Overweight and set a new price target of $113.00 from $87.00 previously
BofA Securities resumed coverage of Gilead Sciences with a rating of Buy and set a new price target of $109.00
Wolfe Research initiated coverage of Gilead Sciences with a rating of Outperform and set a new price target of $110.00
Citigroup initiated coverage of Gilead Sciences with a rating of Buy and set a new price target of $125.00
Maxim Group downgraded Gilead Sciences from Buy to Hold
Leerink Partners upgraded Gilead Sciences from Market Perform to Outperform and set a new price target of $96.00 from $74.00 previously
Bernstein initiated coverage of Gilead Sciences with a rating of Outperform and set a new price target of $105.00
Wells Fargo upgraded Gilead Sciences from Equal Weight to Overweight and set a new price target of $100.00 from $78.00 previously
Raymond James upgraded Gilead Sciences from Mkt Perform to Outperform and set a new price target of $93.00
Maxim Group reiterated coverage of Gilead Sciences with a rating of Buy and set a new price target of $85.00 from $90.00 previously
-- Strategic Partnership Strengthens Gilead's Inflammation Research Portfolio with the Addition of LEO Pharma's Preclinical Oral STAT6 Program, Including Targeted Protein Degraders -- -- Gilead Will Have Exclusive Global Rights to the STAT6 Program, and LEO Pharma Will Have the Option to Co-Commercialize for Dermatology Indications Outside the U.S. -- -- LEO Pharma to Maintain Global Rights to Topical Formulations of the STAT6 Program in Dermatology -- Gilead Sciences, Inc. (NASDAQ:GILD) and LEO Pharma today announced a strategic partnership to accelerate the development and commercialization of LEO Pharma's small molecule oral STAT6 (signal transducer and activator of transcription 6
Gilead Sciences, Inc. (NASDAQ:GILD) announced today that its executives will be speaking at the following investor conference: J.P. Morgan Healthcare Conference on Monday, January 13, 2025 beginning at 11:15 a.m. Pacific Time The live webcast can be accessed at investors.gilead.com and the replay will be available for at least 30 days following the presentation. About Gilead Sciences Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening disease
Gilead Sciences, Inc. (NASDAQ:GILD) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to Trodelvy® (sacituzumab govitecan-hziy) for the treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC) whose disease has progressed on or after platinum-based chemotherapy. The Breakthrough Therapy Designation is based on results from the global Phase 2 TROPiCS-03 study ES-SCLC cohort, which showed encouraging results with Trodelvy as a second-line treatment for ES-SCLC. As recently presented at the IASLC 2024 World Conference on Lung Cancer, Trodelvy demonstrated promising antitumor activity in both platinum-resista
-- Gilead and Terray Will Leverage Terray's tNova Drug Discovery Platform to Identify Small Molecule Therapeutics Against Targets of Interest -- -- Gilead Has Exclusive Option to Develop and Commercialize Products from the Collaboration -- Gilead Sciences, Inc. (NASDAQ:GILD) and Terray Therapeutics, Inc. announced today that the companies have entered into a strategic collaboration to discover and develop novel, small molecule therapies across multiple targets. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241217141411/en/ Terray's tNova platform combines high-throughput chemical experimentation and computational analysis w
– Recommendation Based on the RESPONSE Study Which Demonstrated ALP Normalization in 25% of Participants at 12 Months and Statistically Significant Reduction of Pruritus Versus Placebo – – If Approved by the European Commission, Seladelpar Would Provide an Important Treatment Option for People Living with the Rare Liver Disease in the EU – Gilead Sciences, Inc. (NASDAQ:GILD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending seladelpar for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults who have an inadequate response to
Gilead Sciences, Inc. (NASDAQ:GILD) today announced that Dietmar Berger, MD, PhD, will join the company on January 2, 2025, as Chief Medical Officer and will become a member of Gilead's senior leadership team. Dr. Berger succeeds Merdad Parsey, MD, PhD. Dr. Berger is a board-certified internist, hematologist and oncologist who brings more than 25 years of extensive experience in developing and delivering innovative medicines across a broad range of therapeutic areas. He will assume responsibility for the Company's leading virology, oncology and inflammation portfolio and will oversee the company's global Development and Medical Affairs organizations. "Dietmar's exceptional leadership in
– ZUMA-5 Analysis Shows Median Progression-Free Survival of 62.2 Months and Median Duration of Response of 60.4 Months After Median Follow-Up of More Than Five Years – – Over Half of Patients Alive at Time of Analysis, with No Need for Subsequent Therapy and Rare Instances of Late Disease Progression, Indicating Curative Potential – Kite, a Gilead Company (NASDAQ:GILD), today announced results from a five-year follow-up analysis of ZUMA-5, a Phase 2 study of Yescarta® (axicabtagene ciloleucel) in patients with relapsed/refractory non-Hodgkin lymphomas (NHL) including follicular lymphoma (FL) or marginal zone lymphoma (MZL). The analysis demonstrated that after a median follow-up of more
– Only CAR T to Demonstrate Prolonged Overall Survival After Five Years Follow-Up in Relapsed/Refractory Mantle Cell Lymphoma – – ZUMA-2 Analysis Shows 91% Overall Response Rate, Including 73% Complete Response Rate, in Bruton Tyrosine Kinase Inhibitor-Naïve R/R MCL Patients – – Real-World Evidence Analysis Shows High Effectiveness and Safety Profile Consistent with ZUMA-3 in Broader Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia Population – Kite, a Gilead Company (NASDAQ:GILD), announced results today from four analyses that continue to demonstrate the durability of response of Tecartus® (brexucabtagene autoleucel) in patients with relapsed/refractory mantle cell
– Largest Real-World Evidence (RWE) Analysis of Yescarta in Second-Line Shows 71% Overall Survival Rate, Consistent with Pivotal ZUMA-7 Study, in Broader Patient Population with Relapsed/Refractory Large B-cell Lymphoma (R/R LBCL) – – RWE Shows Decreasing Trend Over Time of Cytokine Release Syndrome and Related Adverse Events After Yescarta Treatment in Third-Line Plus Setting – – Findings from ALYCANTE Study Show Stable Long-Term Quality of Life for R/R LBCL Patients Treated with Yescarta – Kite, a Gilead Company (NASDAQ:GILD), today announced findings from three new analyses for Yescarta® (axicabtagene ciloleucel) that demonstrate improved outcomes for people living with relapsed or
– Single-Asset Focused Collaboration, License, and Option Agreement Combines Tubulis' Differentiated ADC Platform Technologies with Gilead's Oncology Research and Development Expertise – – Agreement Provides Gilead with Exclusive Option to License the Resulting ADC Program for Further Development – Gilead Sciences, Inc. (NASDAQ:GILD) and Tubulis today announced that they have entered into an exclusive option and license agreement to discover and develop an antibody-drug conjugate (ADC) against a solid tumor target. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241203665344/en/ Through this agreement, Gilead will gain access
4 - GILEAD SCIENCES, INC. (0000882095) (Reporting)
144 - GILEAD SCIENCES, INC. (0000882095) (Subject)
8-K - GILEAD SCIENCES, INC. (0000882095) (Filer)
424B5 - GILEAD SCIENCES, INC. (0000882095) (Filer)
FWP - GILEAD SCIENCES, INC. (0000882095) (Subject)
424B5 - GILEAD SCIENCES, INC. (0000882095) (Filer)
10-Q - GILEAD SCIENCES, INC. (0000882095) (Filer)
8-K - GILEAD SCIENCES, INC. (0000882095) (Filer)
10-Q - GILEAD SCIENCES, INC. (0000882095) (Filer)
8-K - GILEAD SCIENCES, INC. (0000882095) (Filer)
8-K - GILEAD SCIENCES, INC. (0000882095) (Filer)
4 - GILEAD SCIENCES, INC. (0000882095) (Issuer)
4 - GILEAD SCIENCES, INC. (0000882095) (Issuer)
3 - GILEAD SCIENCES, INC. (0000882095) (Issuer)
4 - GILEAD SCIENCES, INC. (0000882095) (Issuer)
4 - GILEAD SCIENCES, INC. (0000882095) (Issuer)
4 - GILEAD SCIENCES, INC. (0000882095) (Issuer)
4 - GILEAD SCIENCES, INC. (0000882095) (Issuer)
4 - GILEAD SCIENCES, INC. (0000882095) (Issuer)
4 - GILEAD SCIENCES, INC. (0000882095) (Issuer)
4 - GILEAD SCIENCES, INC. (0000882095) (Issuer)
SC 13G/A - GILEAD SCIENCES, INC. (0000882095) (Subject)
SC 13G/A - GILEAD SCIENCES, INC. (0000882095) (Subject)
SC 13G - GILEAD SCIENCES, INC. (0000882095) (Subject)
SC 13G/A - GILEAD SCIENCES, INC. (0000882095) (Subject)
SC 13G/A - GILEAD SCIENCES INC (0000882095) (Subject)
SC 13G/A - GILEAD SCIENCES INC (0000882095) (Subject)
SC 13G/A - GILEAD SCIENCES INC (0000882095) (Subject)
SC 13G/A - GILEAD SCIENCES INC (0000882095) (Subject)
SC 13G/A - GILEAD SCIENCES INC (0000882095) (Subject)
Product Sales Excluding Veklury Increased 7% Year-Over-Year to $6.8 billion Biktarvy Sales Increased 13% Year-Over-Year to $3.5 billion Oncology Sales Increased 6% Year-Over-Year to $816 million Gilead Sciences, Inc. (NASDAQ:GILD) announced today its third quarter 2024 results of operations. "Gilead's third quarter results are the strongest of the year to date, with 7% year-over-year revenue growth, including 13% year-over-year growth for Biktarvy. Based on this very strong topline growth and disciplined operating expense management, we are increasing our full year revenue, operating income, and earnings per share guidance," said Daniel O'Day, Gilead's Chairman and Chief Executive Offic
Gilead Sciences, Inc. (NASDAQ:GILD) announced today that its third quarter 2024 financial results and guidance will be released on Wednesday, November 6, 2024, after the market closes. At 4:30 p.m. Eastern Time that day, Gilead's management will host a webcast to discuss the company's third quarter 2024 financial results and provide a business update. A live webcast will be available on the Investor Relations section of www.gilead.com and will be archived there for one year. About Gilead Sciences Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all peop
Product Sales Excluding Veklury Increased 6% Year-Over-Year to $6.7 billion Biktarvy Sales Increased 8% Year-Over-Year to $3.2 billion Oncology Sales Increased 15% Year-Over-Year to $841 million Gilead Sciences, Inc. (NASDAQ:GILD) announced today its second quarter 2024 results of operations. "Gilead has had another strong quarter with 6% year-over-year growth in our base business. This was driven by sales of our therapies for HIV, Oncology and Liver Disease, including 8% growth for Biktarvy," said Daniel O'Day, Gilead's Chairman and Chief Executive Officer. "One of the key highlights of the quarter was interim data from the Phase 3 PURPOSE 1 trial showing 100% efficacy for lenacapa
Gilead Sciences, Inc. (NASDAQ:GILD) announced today that its second quarter 2024 financial results and guidance will be released on Thursday, August 8, 2024, after the market closes. At 4:30 p.m. Eastern Time that day, Gilead's management will host a webcast to discuss the company's second quarter 2024 financial results and provide a business update. A live webcast will be available on the Investor Relations section of www.gilead.com and will be archived there for one year. About Gilead Sciences Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all pe
Product Sales Excluding Veklury Increased 6% Year-Over-Year to $6.1 billion Biktarvy Sales Increased 10% Year-Over-Year to $2.9 billion Oncology Sales Increased 18% Year-Over-Year to $789 million Closed CymaBay Acquisition Resulting in $3.9 billion Acquired IPR&D Charge ($3.14 Diluted EPS Impact) Gilead Sciences, Inc. (NASDAQ:GILD) announced today its first quarter 2024 results of operations. "Gilead delivered another strong quarter of revenue growth in the first quarter with 6% year-over-year growth in our base business driven by HIV, Oncology and Liver Disease," said Daniel O'Day, Gilead's Chairman and Chief Executive Officer. "The acquisition of CymaBay brings us another potent
Gilead Sciences, Inc. (NASDAQ:GILD) announced today that its first quarter 2024 financial results and guidance will be released on Thursday, April 25, 2024, after the market closes. At 4:30 p.m. Eastern Time that day, Gilead's management will host a webcast to discuss the company's first quarter 2024 financial results and provide a business update. A live webcast will be available on the Investor Relations section of www.gilead.com and will be archived there for one year. About Gilead Sciences Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all peop
Gilead Sciences, Inc. (NASDAQ:GILD) today announced that the company's Board of Directors has declared an increase of 2.7% in the company's quarterly cash dividend, beginning in the first quarter of 2024. The increase will result in a quarterly dividend of $0.77 per share of common stock. The dividend is payable on March 28, 2024, to stockholders of record at the close of business on March 15, 2024. Future dividends will be subject to Board approval. About Gilead Sciences Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is commi
Product Sales Excluding Veklury Increased Year-Over-Year by 7% for Full Year 2023 Biktarvy Sales Increased Year-Over-Year by 14% for Full Year 2023 Oncology Sales Increased Year-Over-Year by 37% for Full Year 2023 Gilead Sciences, Inc. (NASDAQ:GILD) announced today its results of operations for the fourth quarter and full year 2023. "This was another strong year of revenue growth for Gilead's base business, driven by both HIV and Oncology," said Daniel O'Day, Gilead's Chairman and Chief Executive Officer. "The strength of the business provides a solid foundation as we enter a new catalyst-rich phase for the company. We are expecting several milestones in 2024, including updates on l
Gilead Sciences, Inc. (NASDAQ:GILD) announced today that its fourth quarter and full year 2023 financial results and guidance will be released on Tuesday, February 6, 2024 after the market closes. At 5:00 p.m. Eastern Time that day, Gilead's management will host a webcast to discuss the company's fourth quarter and full year 2023 financial results and provide a business update. A live webcast will be available on the Investor Relations section of www.gilead.com and will be archived there for one year. About Gilead Sciences Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating
Product Sales Excluding Veklury Increased 5% Year-Over-Year to $6.4 billion Biktarvy Sales Increased 12% Year-Over-Year to $3.1 billion Oncology Sales Increased 33% Year-Over-Year to $769 million Gilead Sciences, Inc. (NASDAQ:GILD) announced today its results of operations for the third quarter of 2023. "Gilead has now delivered two years of consistent growth in our base business. In the third quarter, this continued growth was driven by both Virology and Oncology," said Daniel O'Day, Gilead's Chairman and Chief Executive Officer. "Our clinical momentum also remains strong, and highlights this quarter included new data on Trodelvy with pembrolizumab in first-line metastatic non-smal
Submission status for GILEAD SCIENCES INC's drug SUNLENCA (SUPPL-6) with active ingredient LENACAPAVIR SODIUM has changed to 'Approval' on 11/25/2024. Application Category: NDA, Application Number: 215973, Application Classification: Efficacy
Submission status for GILEAD SCIENCES INC's drug SUNLENCA (SUPPL-8) with active ingredient LENACAPAVIR SODIUM has changed to 'Approval' on 11/25/2024. Application Category: NDA, Application Number: 215974, Application Classification: Efficacy
Submission status for GILEAD SCIENCES INC's drug SUNLENCA (SUPPL-9) with active ingredient LENACAPAVIR SODIUM has changed to 'Approval' on 11/13/2024. Application Category: NDA, Application Number: 215973, Application Classification: Manufacturing (CMC)
Submission status for GILEAD SCIENCES INC's drug SUNLENCA (SUPPL-9) with active ingredient LENACAPAVIR SODIUM has changed to 'Approval' on 11/13/2024. Application Category: NDA, Application Number: 215974, Application Classification: Labeling
Submission status for GILEAD SCIENCES INC's drug BIKTARVY (SUPPL-20) with active ingredient BICTEGRAVIR SODIUM; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE has changed to 'Approval' on 10/08/2024. Application Category: NDA, Application Number: 210251, Application Classification: Manufacturing (CMC)
Submission status for GILEAD SCIENCES INC's drug SUNLENCA (SUPPL-7) with active ingredient LENACAPAVIR SODIUM has changed to 'Approval' on 07/17/2024. Application Category: NDA, Application Number: 215974, Application Classification: Labeling
Submission status for GILEAD SCIENCES INC's drug SUNLENCA (SUPPL-5) with active ingredient LENACAPAVIR SODIUM has changed to 'Approval' on 07/17/2024. Application Category: NDA, Application Number: 215973, Application Classification: Labeling
Submission status for GILEAD SCIENCES INC's drug VEKLURY (SUPPL-27) with active ingredient REMDESIVIR has changed to 'Approval' on 06/27/2024. Application Category: NDA, Application Number: 214787, Application Classification: Labeling
Submission status for GILEAD SCIENCES INC's drug BIKTARVY (SUPPL-19) with active ingredient BICTEGRAVIR SODIUM; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE has changed to 'Approval' on 04/24/2024. Application Category: NDA, Application Number: 210251, Application Classification: Efficacy
Submission status for GILEAD SCIENCES INC's drug VEMLIDY (SUPPL-16) with active ingredient TENOFOVIR ALAFENAMIDE FUMARATE has changed to 'Approval' on 03/27/2024. Application Category: NDA, Application Number: 208464, Application Classification: Efficacy
Gilead Sciences, Inc. (NASDAQ:GILD) today announced that Dietmar Berger, MD, PhD, will join the company on January 2, 2025, as Chief Medical Officer and will become a member of Gilead's senior leadership team. Dr. Berger succeeds Merdad Parsey, MD, PhD. Dr. Berger is a board-certified internist, hematologist and oncologist who brings more than 25 years of extensive experience in developing and delivering innovative medicines across a broad range of therapeutic areas. He will assume responsibility for the Company's leading virology, oncology and inflammation portfolio and will oversee the company's global Development and Medical Affairs organizations. "Dietmar's exceptional leadership in
Mechelen, Belgium; 15 June 2023, 22:01 CET; regulated information – Galapagos NV ((Euronext &, NASDAQ:GLPG) today announced the appointment of Thad Huston as Chief Financial Officer (CFO) and Chief Operating Officer (COO) as per 1 July 2023. Mr. Huston will be a member of the Executive Committee of Galapagos and will join Galapagos from Kite, a Gilead Company (NASDAQ:GILD). He brings 30 years of global finance and operational experience in healthcare with an excellent track record of driving business transformation and innovation. "On behalf of the Board of Directors and management of Galapagos, I extend a warm welcome to Thad. Thad is a widely recognized leader with a strong internationa
Gilead Sciences, Inc. (NASDAQ:GILD) today announced that Cindy Perettie will join the company as Executive Vice President of Kite, a Gilead Company, overseeing the cell therapy business, and will become a member of Gilead's senior leadership team, effective May 30. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230516005214/en/Gilead Appoints Cindy Perettie Executive Vice President of Kite (Photo: Business Wire) Ms. Perettie brings with her extensive experience in oncology and a commitment to improving patient care. Most recently, she was Head of Roche's Molecular Lab Solutions where she oversaw the PCR (polymerase chain reactio
MONTREAL, Nov. 29, 2022 /PRNewswire/ - Thryv Therapeutics Inc. is pleased to announce the appointment of Melissa Koomey to its Board of Directors. Ms. Koomey brings an impressive depth of experience in product commercialization, launch and marketing execution, which will be crucial as Thryv advances its development programs in rare arrhythmias such as Long QT Syndrome and advanced cancers. "We are excited to have Melissa join the Thryv Board of Directors at this pivotal time in our story. Our lead compound will emerge from initial safety studies early in 2023 and we will accelerate into efficacy trials with Melissa's experience and insights in Long QT Syndrome," said Paul F. Truex, Thryv's
– Brett Pletcher, Executive Vice President, Corporate Affairs and General Counsel to Retire After 17 Years at Gilead – Gilead Sciences, Inc. (NASDAQ:GILD) announced today that Deborah Telman will join the company as Executive Vice President, Corporate Affairs and General Counsel, and will become a member of the company's senior leadership team, reporting to Chairman and Chief Executive Officer Daniel O'Day. Ms. Telman will assume responsibility for Gilead's legal and corporate affairs function, which includes government and policy, and public affairs. Ms. Telman will start in her new role August 1, 2022. She will also become Corporate Secretary of Gilead. Ms. Telman will succeed Brett Plet
– Taiyin Yang, PhD, Executive Vice President, Pharmaceutical Development and Manufacturing to Retire After 29 Years at Gilead – Gilead Sciences, Inc. (NASDAQ:GILD) announced today that Stacey Ma, PhD will join the company as Executive Vice President, Pharmaceutical Development and Manufacturing, and will become a member of the company's senior leadership team, reporting to Chairman and Chief Executive Officer Daniel O'Day. Dr. Ma will assume responsibility for Gilead's Pharmaceutical Development and Manufacturing organization effective July 18, 2022. Dr. Ma will succeed Dr. Yang, who is retiring from Gilead after nearly three decades. Dr. Ma brings to her new role more than 25 years of ex
Eikon Therapeutics Inc., a California-based biotechnology company that applies advanced engineering and high-performance computing to the identification of important new medicines, today announced the appointment of Robin L. Washington as an independent director effective May 12, 2022. Ms. Washington is among the most experienced business leaders in the biopharmaceutical and technology industries, having served as Chief Financial Officer at Gilead, Inc. from 2008 until 2019, managing global finance, investor relations, facilities and operations, and information technology during a period when corporate revenue grew by more than six-fold. This press release features multimedia. View the full
Mr. Allan, the 2017 winner of the prestigious Julia Levy Award, to collaborate with 2021 Julia Levy Award winner Dr. Lakshmi P. Kotra, CEO of FSD Pharma subsidiary Lucid Psycheceuticals FSD Pharma Inc. (NASDAQ:HUGE) (CSE:HUGE) (FRE: 0K9A) ("FSD Pharma" or the "Company"), a life sciences holding company dedicated to building a portfolio of assets and biotech solutions, announced the appointment of David Allan and John McGraw, PhD, MSc, to the Company's Advisory Board. "Mr. Allan and Dr. McGraw both have impressive careers in the field of healthcare and biotechnology underscored by tremendously successful exits and we are excited to welcome them to our team," commented Anthony Durkacz, Foun
NEWARK, N.J., June 14, 2021 /PRNewswire/ -- Rafael Holdings, Inc., (NYSE:RFL), a pharmaceutical company focused on developing novel cancer metabolism therapeutics, today announced the appointment of three senior biopharmaceutical leaders to its Board of Directors: Ameet Mallik, Chief Executive Officer of Rafael Holdings; Shannon Thyme Klinger, Chief Legal Officer of Moderna, Inc., (NASDAQ GS: MRNA); and Mark McCamish, M.D., Ph.D., President and Chief Executive Officer of IconOVir Bio. www.rafaelholdings.com (PRNewsfoto/Rafael Holdings, Inc.)" alt="Rafael Holdings holds commercial real estate assets and interests in two clini
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that Flavius Martin, MD will join the company as Executive Vice President, Research, and will become a member of the company’s senior leadership team, reporting to Chairman and Chief Executive Officer Daniel O’Day. Dr. Martin will assume responsibility for Gilead’s research organization effective April 12, 2021. Bill Lee, PhD, is retiring from Gilead after three decades. Dr. Martin brings to his new role significant experience overseeing industry-leading research, with particular expertise in oncology and inflammation. He joins Gilead from Amgen, Inc., where he most recently served as Vice Pr